KR950016725A - 폐 고혈압성 질병을 억제하는 방법 - Google Patents
폐 고혈압성 질병을 억제하는 방법 Download PDFInfo
- Publication number
- KR950016725A KR950016725A KR1019940034916A KR19940034916A KR950016725A KR 950016725 A KR950016725 A KR 950016725A KR 1019940034916 A KR1019940034916 A KR 1019940034916A KR 19940034916 A KR19940034916 A KR 19940034916A KR 950016725 A KR950016725 A KR 950016725A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pulmonary hypertension
- formula
- hypertension diseases
- suppress pulmonary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
본 발명은 폐 고혈압성 질병의 억제를 필요로하는 인간에게 효과량의 하기 일반식(I)의 화합물 또는 약학적으로 허용가능한 그의 염 또는 용매화물을 투여함을 포함하는 폐 고혈압성 질병을 억제하는 방법에 관한 것이다:
상기식에서,
R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노, 헥사메틸렌이미노 및 피페리디노로 이루어진 그룹중에서 선택된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (4)
- 폐 고혈얍성 질병을 억제하는데 사용하기 위한 하기 일반식(I)의 화합물 또는 약학적으로 허용가능한 그의 염 또는 용매화물:상기식에서,R1및 R3는 독립적으로 수소, -CH3,(여기에서, Ar은 임의로 치환된 페닐이다)이고; R2는 피롤리디노 및 피페리디노로 이루어진 그룹중에서 선택된다.
- 제1항에 있어서, 상기 화합물이 그의 염산 염인 화합물.
- 제1항에 있어서, 예방목적으로 투여하는 화합물.
- 제1항에 있어서, 상기 화합물이 하기 구조식의 화합물 또는 그의 염산 염인 화합물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/171,386 | 1993-12-21 | ||
US08/171,386 US5447941A (en) | 1993-12-21 | 1993-12-21 | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
Publications (1)
Publication Number | Publication Date |
---|---|
KR950016725A true KR950016725A (ko) | 1995-07-20 |
Family
ID=22623551
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019940034916A KR950016725A (ko) | 1993-12-21 | 1994-12-19 | 폐 고혈압성 질병을 억제하는 방법 |
Country Status (13)
Country | Link |
---|---|
US (1) | US5447941A (ko) |
EP (1) | EP0659426A1 (ko) |
JP (1) | JPH07215856A (ko) |
KR (1) | KR950016725A (ko) |
CN (1) | CN1109753A (ko) |
AU (1) | AU8154994A (ko) |
CA (1) | CA2138496A1 (ko) |
CZ (1) | CZ320894A3 (ko) |
HU (1) | HUT71222A (ko) |
IL (1) | IL112033A0 (ko) |
NO (1) | NO944927L (ko) |
RU (1) | RU94045149A (ko) |
ZA (1) | ZA9410100B (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6251920B1 (en) | 1993-05-13 | 2001-06-26 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
US5847007A (en) | 1993-05-13 | 1998-12-08 | Neorx Corporation | Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells |
US6491938B2 (en) | 1993-05-13 | 2002-12-10 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5595722A (en) | 1993-01-28 | 1997-01-21 | Neorx Corporation | Method for identifying an agent which increases TGF-beta levels |
US6562862B1 (en) * | 1994-10-20 | 2003-05-13 | Eli Lilly And Company | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
AU6277396A (en) | 1995-06-07 | 1996-12-30 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies with tamoxifen analogues |
US5840747A (en) * | 1995-06-07 | 1998-11-24 | Eli Lilly And Company | Calcium channel antagonists |
TW442286B (en) * | 1996-02-28 | 2001-06-23 | Pfizer | New therapeutic uses of estrogen agonists |
IL120266A (en) | 1996-02-28 | 2005-05-17 | Pfizer | Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions |
US5811437A (en) * | 1996-05-21 | 1998-09-22 | Eli Lilly And Company | Methods of increasing nitric oxide synthesis |
US6693130B2 (en) * | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
AU6959898A (en) * | 1997-04-11 | 1998-11-11 | David J. Grainger | Compounds and therapies for the prevention of vascular and non-vascular pathol ogies |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
WO2000045806A1 (en) * | 1999-02-03 | 2000-08-10 | Eli Lilly And Company | α1-ADRENERGIC RECEPTOR ANTAGONISTS |
CA2372720C (en) | 1999-05-04 | 2007-09-11 | John Antony Kanis | Androgen glycosides and androgenic activity thereof |
EP1233811A2 (en) * | 1999-11-12 | 2002-08-28 | Leo Rubin | Methods for treating cardiac arrest or pulmonary hypertension and compositions for use therein comprising vasoactive intestinal polypeptide and cardiac device for electrical and chemical regulation and methods of use |
GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
GB2374412A (en) * | 2001-04-11 | 2002-10-16 | Karobio Ab | Hypertension treatment and assay |
US6854563B2 (en) * | 2001-12-17 | 2005-02-15 | General Electric Company | Wayside rail lubrication apparatus and method |
TW200740442A (en) * | 2005-08-29 | 2007-11-01 | Taiho Pharmaceutical Co Ltd | Therapeutic agent for hypertension |
WO2011099942A1 (en) | 2010-02-09 | 2011-08-18 | Silverstone Pharma | New addition salts of raloxifene, process for the preparation thereof and use thereof in therapy |
GB201705124D0 (en) | 2017-03-30 | 2017-05-17 | Innospec Ltd | Composition, method and use |
KR102132554B1 (ko) * | 2019-02-25 | 2020-07-09 | 가톨릭대학교 산학협력단 | 랄록시펜을 유효성분으로 함유하는 전신경화증의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3947470A (en) * | 1974-06-20 | 1976-03-30 | Smithkline Corporation | Substituted benzofurans and benzothiophenes |
US4133814A (en) * | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
US4418068A (en) * | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
US4380635A (en) * | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
US5075321A (en) * | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
JP3157882B2 (ja) * | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
-
1993
- 1993-12-21 US US08/171,386 patent/US5447941A/en not_active Expired - Fee Related
-
1994
- 1994-12-19 JP JP6314539A patent/JPH07215856A/ja active Pending
- 1994-12-19 EP EP94309484A patent/EP0659426A1/en not_active Withdrawn
- 1994-12-19 AU AU81549/94A patent/AU8154994A/en not_active Abandoned
- 1994-12-19 NO NO944927A patent/NO944927L/no unknown
- 1994-12-19 CZ CZ943208A patent/CZ320894A3/cs unknown
- 1994-12-19 KR KR1019940034916A patent/KR950016725A/ko not_active Application Discontinuation
- 1994-12-19 IL IL11203394A patent/IL112033A0/xx unknown
- 1994-12-19 CN CN94119744A patent/CN1109753A/zh active Pending
- 1994-12-19 HU HU9403657A patent/HUT71222A/hu unknown
- 1994-12-19 ZA ZA9410100A patent/ZA9410100B/xx unknown
- 1994-12-19 CA CA002138496A patent/CA2138496A1/en not_active Abandoned
- 1994-12-19 RU RU94045149/14A patent/RU94045149A/ru unknown
Also Published As
Publication number | Publication date |
---|---|
CZ320894A3 (en) | 1995-08-16 |
CN1109753A (zh) | 1995-10-11 |
EP0659426A1 (en) | 1995-06-28 |
JPH07215856A (ja) | 1995-08-15 |
NO944927D0 (no) | 1994-12-19 |
US5447941A (en) | 1995-09-05 |
HUT71222A (en) | 1995-11-28 |
ZA9410100B (en) | 1996-06-19 |
HU9403657D0 (en) | 1995-02-28 |
IL112033A0 (en) | 1995-03-15 |
RU94045149A (ru) | 1996-10-20 |
NO944927L (no) | 1995-06-22 |
AU8154994A (en) | 1995-06-29 |
CA2138496A1 (en) | 1995-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR950016725A (ko) | 폐 고혈압성 질병을 억제하는 방법 | |
KR970706818A (ko) | 뉴로펩티드 y와 관련된 상태의 억제 방법(methods of inhibiting conditions associated with neuropeptide) | |
KR950016738A (ko) | 알쯔하이머 질병의 억제 방법 | |
KR950016744A (ko) | 트롬빈을 저해하는 방법 | |
KR950016746A (ko) | 비-펩티드 타키키닌 수용체 길항물질 | |
KR950016732A (ko) | 피부 및 질의 위축 억제방법 | |
KR950016731A (ko) | 지루 및 좌창의 억제 방법 | |
KR950010893A (ko) | 자궁내막증 억제 방법 | |
KR950016723A (ko) | 자가면역 질병의 억제 방법 | |
KR950010892A (ko) | 자궁 섬유증 억제 방법 | |
KR950016726A (ko) | 기능부전성 자궁 출혈을 억제하는 방법 | |
KR950016745A (ko) | 생리증상의 치료방법 및 이를 위한 조성물 | |
RU97108050A (ru) | Способ ингибирования состояний, связанных с нейропептидом y | |
KR950017957A (ko) | 3, 4, 4-삼치환-피페리디닐-n-알킬카르복실레이트의 제법 및 중간체 | |
KR950016740A (ko) | 조직의 불완전한 회복을 저해하는 방법 | |
KR950016737A (ko) | 생리전 증후군/후기 황체 시기 불쾌성 질환 증상의 억제 방법 | |
KR950016730A (ko) | 폐경기 후 증후군과 관련한 혈관 운동 증상 및 수반되는 심리학적 장애의 억제 방법 | |
KR950010889A (ko) | 혈관형성 및 혈관형성성 질병을 억제하는 방법 | |
KR950016727A (ko) | 트롬보모듈린 발현을 증가시키는 방법 | |
KR950016724A (ko) | 폐경기 후 여성의 리비도를 증가시키는 방법 | |
KR950010891A (ko) | 내성 종양을 치료하는 방법 | |
KR950010886A (ko) | 혈청 콜레스테롤의 강하 방법 | |
KR950010887A (ko) | 연골 퇴화 억제 방법 | |
KR950016742A (ko) | 폐경후 여성의 씨엔에스 질환을 억제하는 방법 | |
KR950016735A (ko) | 터너 증후군의 억제 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |